Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jin-Ji Yang

Showing results (11-20 of 176) with videos related to

Pageof 18
Sort By:
Thoracic Cancer|November 2, 2016
Heterogeneity of the resistance to gefitinib treatment in a non-small cell lung cancer patient with active epidermal growth factor receptor mutationChong-Rui Xu, Wen-Zhao Zhong, Qing Zhou, et al.
The International Journal of Biological Markers|July 23, 2013
Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in males, smokers, and non-adenocarcinoma lung cancer in patients with EGFR mutationsZhu Zeng, Hua-Jun Chen, Hong-Hong Yan, et al.
Nuclear Medicine Communications|September 22, 2011
Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?Jin-Ji Yang, Shu-Xia Wang, Wen-Zhao Zhong, et al.
BMC Cancer|October 16, 2015
Multiple primary malignancies involving lung cancerFeng Li, Wen-Zhao Zhong, Fei-Yu Niu, et al.
Cancer Drug Resistance (Alhambra, Calif.)|March 7, 2025
Exploring YAP1-related TIME in SCLC: implications for survival and treatment response to immuno-chemotherapyYu-Qing Chen, Jia-Xiong Tan, Ling-Ling Gao, et al.
Thoracic Cancer|April 16, 2020
Mutational landscape and characteristics of ERBB2 in non-small cell lung cancerXue-Wu Wei, Xin Gao, Xu-Chao Zhang, et al.
Chinese Medical Journal|June 7, 2017
Establishment of a Novel Method for Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Mutations in Lung CancerHong-Xia Tian, Xu-Chao Zhang, Zhen Wang, et al.
Pathology Oncology Research : POR|May 30, 2013
Disease flare after EGFR tyrosine kinase inhibitor cessation predicts poor survival in patients with non-small cell lung cancerHua-Jun Chen, Hong-Hong Yan, Jin-Ji Yang, et al.
BMC Cancer|September 21, 2014
A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lungJin-Ji Yang, Cheng Huang, Gong-Yan Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|November 28, 2017
Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patientsHong-Xia Tian, Xu-Chao Zhang, Jin-Ji Yang, et al.
Pageof 18

Showing results (11-20 of 176) with videos related to

Sort By:
Pageof 18
Thoracic Cancer|November 2, 2016
Heterogeneity of the resistance to gefitinib treatment in a non-small cell lung cancer patient with active epidermal growth factor receptor mutationChong-Rui Xu, Wen-Zhao Zhong, Qing Zhou, et al.
The International Journal of Biological Markers|July 23, 2013
Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in males, smokers, and non-adenocarcinoma lung cancer in patients with EGFR mutationsZhu Zeng, Hua-Jun Chen, Hong-Hong Yan, et al.
Nuclear Medicine Communications|September 22, 2011
Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?Jin-Ji Yang, Shu-Xia Wang, Wen-Zhao Zhong, et al.
BMC Cancer|October 16, 2015
Multiple primary malignancies involving lung cancerFeng Li, Wen-Zhao Zhong, Fei-Yu Niu, et al.
Cancer Drug Resistance (Alhambra, Calif.)|March 7, 2025
Exploring YAP1-related TIME in SCLC: implications for survival and treatment response to immuno-chemotherapyYu-Qing Chen, Jia-Xiong Tan, Ling-Ling Gao, et al.
Thoracic Cancer|April 16, 2020
Mutational landscape and characteristics of ERBB2 in non-small cell lung cancerXue-Wu Wei, Xin Gao, Xu-Chao Zhang, et al.
Chinese Medical Journal|June 7, 2017
Establishment of a Novel Method for Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Mutations in Lung CancerHong-Xia Tian, Xu-Chao Zhang, Zhen Wang, et al.
Pathology Oncology Research : POR|May 30, 2013
Disease flare after EGFR tyrosine kinase inhibitor cessation predicts poor survival in patients with non-small cell lung cancerHua-Jun Chen, Hong-Hong Yan, Jin-Ji Yang, et al.
BMC Cancer|September 21, 2014
A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lungJin-Ji Yang, Cheng Huang, Gong-Yan Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|November 28, 2017
Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patientsHong-Xia Tian, Xu-Chao Zhang, Jin-Ji Yang, et al.
Pageof 18